{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:33:50Z","timestamp":1787070830664,"version":"build-2736575974"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The prevalence of myopia has rapidly increased over the last 30 years, with the World Health Organization estimating a worldwide incidence of 23%, projected to increase to 50% by 2050. The myopia epidemic has prompted a reincarnation in efforts to overcome this challenge. The exploration of atropine use in myopia was a result due to a lack of treatment in effect. This study aimed at reviewing the role of atropine in the management of myopia worldwide based on currently available findings. A literature search was conducted using PubMed\/MEDLINE and Google Scholar for studies published up to April 2022 inclusive. Articles with high or medium clinical relevance were selected for this review. Multiple studies have demonstrated the relevance and efficacy rates of different concentrations of atropine, despite still insufficiently explained the exact site and mechanism of action of atropine in slowing myopia progression. Currently available findings highlight that topical atropine opened a new page in pharmacotherapy of myopia and have shown a high therapeutic effect on myopia progression in Asian and European child population, irrespective of ethnicity. There is potential for myopia control with fewer side effects using lower concentrations but still exists a room for improvement, underscoring the requirement of modified atropine topical preparations with increased bioavailability, potentially with nanoparticle formulations, to enable the effective management of myopia.<\/jats:p>","DOI":"10.4103\/tjo.tjo-d-22-00060","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T06:04:15Z","timestamp":1718949855000},"page":"225-229","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Atropine: Updates on myopia pharmacotherapy"],"prefix":"10.4103","volume":"14","author":[{"given":"Marianne L.","family":"Shahsuvaryan","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Yerevan State Medical University, Yerevan, Armenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,8,25]]},"reference":[{"key":"R2-20240830","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","article-title":"Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050","volume":"123","author":"Holden","year":"2016","journal-title":"Ophthalmology"},{"key":"R3-20240830","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.ophtha.2018.01.033","article-title":"Public health burden and potential interventions for myopia","volume":"125","author":"Modjtahedi","year":"2018","journal-title":"Ophthalmology"},{"key":"R4-20240830","doi-asserted-by":"crossref","first-page":"100923","DOI":"10.1016\/j.preteyeres.2020.100923","article-title":"Efficacy in myopia control","volume":"83","author":"Brennan","year":"2021","journal-title":"Prog Retin Eye Res"},{"key":"R5-20240830","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.ophtha.2021.04.032","article-title":"The risks and benefits of myopia control","volume":"128","author":"Bullimore","year":"2021","journal-title":"Ophthalmology"},{"key":"R6-20240830","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/ICL.0000000000000677","article-title":"Biological mechanisms of atropine control of myopia","volume":"46","author":"Upadhyay","year":"2020","journal-title":"Eye Contact Lens"},{"key":"R7-20240830","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1017\/S0952523800171184","article-title":"Effects of atropine on refractive development, dopamine release, and slow retinal potentials in the chick","volume":"17","author":"Schwahn","year":"2000","journal-title":"Vis Neurosci"},{"key":"R8-20240830","first-page":"1732","article-title":"The ocular growth inhibition effected by dopamine agonists and atropine is associated with transient increases in choroidal thickness in chicks","volume":"49","author":"Dhillon","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R9-20240830","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41433-018-0139-7","article-title":"Update in myopia and treatment strategy of atropine use in myopia control","volume":"33","author":"Wu","year":"2019","journal-title":"Eye (Lond)"},{"key":"R10-20240830","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1016\/j.ophtha.2006.05.062","article-title":"Atropine for the treatment of childhood myopia","volume":"113","author":"Chua","year":"2006","journal-title":"Ophthalmology"},{"key":"R11-20240830","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","article-title":"Atropine for the treatment of childhood myopia: Safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2)","volume":"119","author":"Chia","year":"2012","journal-title":"Ophthalmology"},{"key":"R12-20240830","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/eye.2012.279","article-title":"Prescription of atropine eye drops among children diagnosed with myopia in Taiwan from 2000 to 2007: A nationwide study","volume":"27","author":"Fang","year":"2013","journal-title":"Eye (Lond)"},{"key":"R13-20240830","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1034\/j.1600-0420.2001.790304.x","article-title":"An intervention trial on efficacy of atropine and multi-focal glasses in controlling myopic progression","volume":"79","author":"Shih","year":"2001","journal-title":"Acta Ophthalmol Scand"},{"key":"R14-20240830","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1001\/jamaophthalmol.2017.1091","article-title":"Efficacy and adverse effects of atropine in childhood myopia: A meta-analysis","volume":"135","author":"Gong","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"R15-20240830","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","article-title":"Low-concentration atropine for myopia progression (LAMP) study: A randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control","volume":"126","author":"Yam","year":"2019","journal-title":"Ophthalmology"},{"key":"R16-20240830","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.ophtha.2019.12.011","article-title":"Two-year clinical trial of the low-concentration atropine for myopia progression (LAMP) study: Phase 2 report","volume":"127","author":"Yam","year":"2020","journal-title":"Ophthalmology"},{"key":"R17-20240830","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.ophtha.2020.06.004","article-title":"Differential effects on ocular biometrics by 0.05%, 0.025%, and 0.01% atropine: Low-concentration atropine for myopia progression study","volume":"127","author":"Li","year":"2020","journal-title":"Ophthalmology"},{"key":"R18-20240830","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.ophtha.2020.12.036","article-title":"Age effect on treatment responses to 0.05%, 0.025%, and 0.01% atropine: Low-concentration atropine for myopia progression study","volume":"128","author":"Li","year":"2021","journal-title":"Ophthalmology"},{"key":"R19-20240830","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ajo.2021.12.014","article-title":"The association of choroidal thickening by atropine with treatment effects for myopia: Two-year clinical trial of the low-concentration atropine for myopia progression (LAMP) study","volume":"237","author":"Yam","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"R20-20240830","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1007\/s00417-021-05254-5","article-title":"A retrospective analysis of the therapeutic effects of 0.01% atropine on axial length growth in children in a real-life clinical setting","volume":"259","author":"Kaymak","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R21-20240830","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40123-022-00476-0","article-title":"Short-term effects of atropine 0.01% on the structure and vasculature of the choroid and retina in myopic Chinese children","volume":"11","author":"Wang","year":"2022","journal-title":"Ophthalmol Ther"},{"key":"R22-20240830","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ophtha.2021.10.002","article-title":"Three-year clinical trial of low-concentration atropine for myopia progression (LAMP) study: Continued versus washout: Phase 3 report","volume":"129","author":"Yam","year":"2022","journal-title":"Ophthalmology"},{"key":"R23-20240830","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1136\/bjophthalmol-2015-307861","article-title":"The acceptability and visual impact of 0.01% atropine in a Caucasian population","volume":"100","author":"Loughman","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"R24-20240830","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.oftal.2017.12.015","article-title":"Superdiluted atropine at 0.01% reduces progression in children and adolescents. A 5 year study of safety and effectiveness","volume":"93","author":"Diaz-Llopis","year":"2018","journal-title":"Arch Soc Esp Oftalmol (Engl Ed)"},{"key":"R25-20240830","doi-asserted-by":"crossref","first-page":"e1136","DOI":"10.1111\/aos.14166","article-title":"Efficacy of atropine 0.01% for the treatment of childhood myopia in European patients","volume":"97","author":"Sacchi","year":"2019","journal-title":"Acta Ophthalmol"},{"key":"R26-20240830","doi-asserted-by":"crossref","first-page":"15","DOI":"10.12688\/hrbopenres.12914.1","article-title":"Myopia Outcome Study of Atropine in Children (MOSAIC): An investigator-led, double-masked, placebo-controlled, randomised clinical trial protocol","volume":"2","author":"McCrann","year":"2019","journal-title":"HRB Open Res"},{"key":"R27-20240830","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1177\/1120672121998960","article-title":"Update and guidance on management of myopia. European Society of Ophthalmology in cooperation with International Myopia Institute","volume":"31","author":"N\u00e9meth","year":"2021","journal-title":"Eur J Ophthalmol"},{"key":"R28-20240830","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s10792-021-01755-8","article-title":"Side effects of topical atropine 0.05% compared to 0.01% for myopia control in German school children: A pilot study","volume":"41","author":"Joachimsen","year":"2021","journal-title":"Int Ophthalmol"},{"key":"R29-20240830","first-page":"359","article-title":"Myopia Management. In The Pediatric Eye Exam Quick Reference Guide: Office and Emergency Room Procedures","author":"Singh","year":"2022","journal-title":"IGI Global"},{"key":"R30-20240830","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/eye.2016.78","article-title":"Effectiveness study of atropine for progressive myopia in Europeans","volume":"30","author":"Polling","year":"2016","journal-title":"Eye (Lond)"},{"key":"R31-20240830","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/s41433-020-1122-7","article-title":"A3-year follow-up study of atropine treatment for progressive myopia in Europeans","volume":"34","author":"Polling","year":"2020","journal-title":"Eye (Lond)"},{"key":"R32-20240830","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/opo.12676","article-title":"Myopia management in the Netherlands","volume":"40","author":"Klaver","year":"2020","journal-title":"Ophthalmic Physiol Opt"},{"key":"R33-20240830","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3390\/jcm10040588","article-title":"Corneal penetration of low-dose atropine eye drops","volume":"10","author":"Austermann","year":"2021","journal-title":"J Clin Med"},{"key":"R34-20240830","doi-asserted-by":"crossref","first-page":"756398","DOI":"10.3389\/fmed.2021.756398","article-title":"Varying dose of atropine in slowing myopia progression in children over different follow-up periods by meta-analysis","volume":"8","author":"Gan","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R35-20240830","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ophtha.2021.10.016","article-title":"Efficacy and safety of 8 atropine concentrations for myopia control in children: A network meta-analysis","volume":"129","author":"Ha","year":"2022","journal-title":"Ophthalmology"},{"key":"R36-20240830","doi-asserted-by":"crossref","first-page":"900","DOI":"10.3390\/pharmaceutics14050900","article-title":"The role of atropine in preventing myopia progression: An update","volume":"14","author":"Chierigo","year":"2022","journal-title":"Pharmaceutics"}],"container-title":["Taiwan Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/tjo.TJO-D-22-00060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:37:18Z","timestamp":1787067438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/tjo.TJO-D-22-00060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,25]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/tjo.tjo-d-22-00060","relation":{},"ISSN":["2211-5056","2211-5072"],"issn-type":[{"value":"2211-5056","type":"print"},{"value":"2211-5072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,25]]},"assertion":[{"value":"2022-04-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}